Extended-infusion eptifibatide to prevent stent thrombosis in a patient undergoing orthopedic surgery

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages

  Lizza, Bryan D ^a   Kauflin, Matthew J ^b  

^a Grandview Medical Center   (United States)

^b OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

Eptifibatide; Extended; Hip fracture; Orthopedic; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FONDAPARINUX;

AGED; ANEMIA; ARTICLE; CASE REPORT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; ERYTHROCYTE TRANSFUSION; FEMALE; HIP FRACTURE; HUMAN; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTOPENIA; TREATMENT FAILURE;

AGED, 80 AND OVER; DRUG-ELUTING STENTS; FEMALE; HUMANS; ORTHOPEDICS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 79957583588     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P728     Document Type: Article

References (17)

1. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-1971.
2. Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029.
3. King SB, Smith SC, Hirshfield JW, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 2008;51:172-209.
4. Kushner FG, Hand M, Smith SC, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update): and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2009;54: 2205-2241.
5. Package insert. Plavix (clopidogrel). Bridgewater, NJ: Bristol-Myers Squibb, August 2010.
6. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide Am J Cardiol 1997;80:11B-20B.
7. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-1227.
8. Package insert. Integrilin (eptifibatide). Kenilworth, NJ: Schering Corporation, January 2009.
9. Jaffe R, Halon DA, Carmeli J, et al. Prolonged intravenous eptifibatide infusion for prevention of coronary stent thrombosis. Int J Cardiol 2007; 114:409-11.
10. Pickett AM, Taylor DA, Ackman ML. Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature. Pharmacotherapy 2010; 30:127e-33e.
11. Kirtane AJ, Piazza G, Murphy SA, et al. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide-observations from the PROTECT-TIMI 30 trial. J Am Coll Cardiol 2006;47:2374-239.
12. The PURSUIT Trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
13. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary artery stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356:2037-2044.
14. Hongo RH, Brent BN. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol 2001;88:428-431.
15. Coons JC, Barcelona RA, Freedy T, et al. Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother 2005;39:368-372. DOI 10.1345/aph.1E244
16. Gretler DD, Guerciolini R, Williams PJ. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther 2004;26:390-398.
17. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.